Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, has appointed Shalini Sharp to its Board of Directors and as a member of the Board's Audit Committee, effective September 27, 2024. Ms. Sharp, a leading financial executive with extensive experience in the pharmaceutical and investment banking industries, currently serves on the boards of Neurocrine Biosciences and Organon & Co. She previously held positions as CFO and Executive VP at Ultragenyx and CFO and VP at Agenus.
John V. Oyler, Co-Founder, Chairman and CEO of BeiGene, welcomed Ms. Sharp, highlighting her extensive experience in leading innovative global pharmaceutical companies as valuable for BeiGene's growth phase, market expansion, and pipeline advancement. Ms. Sharp expressed excitement about joining BeiGene's Board, emphasizing the company's commitment to innovation and mission to lower barriers to access worldwide.
BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), un'azienda globale nel settore oncologico, ha nominato Shalini Sharp nel suo Consiglio di Amministrazione e come membro del Comitato di Revisione del Consiglio, con effetto dal 27 settembre 2024. La signora Sharp, una leader nel settore finanziario con una vasta esperienza nelle industrie farmaceutica e bancaria d'investimento, attualmente fa parte dei consigli di amministrazione di Neurocrine Biosciences e Organon & Co. Ha ricoperto in precedenza ruoli di CFO e VP Esecutivo presso Ultragenyx e CFO e VP presso Agenus.
John V. Oyler, Co-Fondatore, Presidente e CEO di BeiGene, ha dato il benvenuto alla signora Sharp, evidenziando la sua ampia esperienza nella guida di aziende farmaceutiche globali innovative come un valore aggiunto per la fase di crescita, espansione di mercato e sviluppo della pipeline di BeiGene. La signora Sharp ha espresso entusiasmo per l'ingresso nel Consiglio di BeiGene, sottolineando l'impegno dell'azienda per l'innovazione e la missione di ridurre le barriere all'accesso in tutto il mondo.
BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), una empresa global de oncología, ha nombrado a Shalini Sharp en su Junta Directiva y como miembro del Comité de Auditoría de la Junta, con efecto a partir del 27 de septiembre de 2024. La Sra. Sharp, una destacada ejecutiva financiera con amplia experiencia en las industrias farmacéutica y de banca de inversión, actualmente forma parte de las juntas de Neurocrine Biosciences y Organon & Co. Anteriormente ocupó puestos como CFO y VP Ejecutiva en Ultragenyx y CFO y VP en Agenus.
John V. Oyler, Co-Fundador, Presidente y CEO de BeiGene, dio la bienvenida a la Sra. Sharp, destacando su amplia experiencia liderando empresas farmacéuticas globales innovadoras como un activo valioso para la fase de crecimiento, expansión de mercado y avance de la cartera de BeiGene. La Sra. Sharp expresó su entusiasmo por unirse a la Junta de BeiGene, enfatizando el compromiso de la empresa con la innovación y su misión de reducir las barreras de acceso en todo el mundo.
BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), 글로벌 온콜로지 회사가 Shalini Sharp을 이사회의 이사로 임명했습니다 및 이사회의 감사위원회 위원으로 2024년 9월 27일부터 효력이 발생합니다. Sharp는 제약 및 투자은행 산업에서 광범위한 경험을 가진 금융 임원이자 Neurocrine Biosciences 및 Organon & Co.의 이사회 멤버로 현재 재직 중입니다. 그녀는 Ultragenyx에서 CFO 및 임원 VP, Agenus에서 CFO 및 VP를 역임한 바 있습니다.
BeiGene의 공동 창립자이자 회장 및 CEO인 John V. Oyler는 Sharp를 환영하며, 그녀의 글로벌 혁신 제약 회사를 이끌었던 광범위한 경험이 BeiGene의 성장 단계, 시장 확장 및 파이프라인 발전에 중요한 가치를 더할 것이라고 강조했습니다. Sharp는 BeiGene의 이사회의 일원이 되는 것에 대한 기대감을 표현하며, 회사의 혁신에 대한 헌신과 전 세계적인 접근 장벽을 낮추기 위한 사명을 강조했습니다.
BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), une entreprise mondiale dans le domaine de l'oncologie, a nommé Shalini Sharp au Conseil d'Administration et comme membre du Comité d'Audit du Conseil, avec effet à partir du 27 septembre 2024. Mme Sharp, une dirigeante financière de premier plan avec une vaste expérience dans les industries pharmaceutiques et de la banque d'investissement, siège actuellement aux conseils d'administration de Neurocrine Biosciences et d'Organon & Co. Elle a précédemment occupé des postes de CFO et de VP Exécutif chez Ultragenyx, ainsi que de CFO et VP chez Agenus.
John V. Oyler, co-fondateur, président et CEO de BeiGene, a accueilli Mme Sharp, soulignant que son expérience approfondie dans la direction d'entreprises pharmaceutiques mondiales innovantes serait précieuse pour la phase de croissance, l'expansion du marché et l'avancement du pipeline de BeiGene. Mme Sharp a exprimé son enthousiasme à rejoindre le Conseil de BeiGene, en mettant l'accent sur l'engagement de l'entreprise envers l'innovation et sa mission de réduire les barrières d'accès dans le monde entier.
BeiGene, (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), ein globales Onkologieunternehmen, hat Shalini Sharp in den Vorstand berufen und als Mitglied des Prüfungsausschusses des Vorstands, mit Wirkung zum 27. September 2024. Frau Sharp, eine führende Finanzexpertin mit umfangreicher Erfahrung in der Pharma- und Investmentbankbranche, ist derzeit Mitglied der Vorstände von Neurocrine Biosciences und Organon & Co. Zuvor hatte sie Positionen als CFO und Executive VP bei Ultragenyx sowie CFO und VP bei Agenus inne.
John V. Oyler, Mitgründer, Vorsitzender und CEO von BeiGene, begrüßte Frau Sharp und hob hervor, dass ihre umfassende Erfahrung in der Leitung innovativer globaler Pharmaunternehmen für die Wachstumsphase, Markterweiterung und Weiterentwicklung der Pipeline von BeiGene von großem Wert sei. Frau Sharp äußerte ihre Begeisterung über den Eintritt in den Vorstand von BeiGene und betonte das Engagement des Unternehmens für Innovation und die Mission, weltweit Zugangshürden abzubauen.
- Appointment of Shalini Sharp, an experienced financial executive, to the Board of Directors
- Addition of Sharp's expertise to guide BeiGene's global growth and market expansion
- Strengthening of the Board's financial oversight with Sharp joining the Audit Committee
- None.
“We are fortunate to welcome Shalini to the Board of Directors at this pivotal moment of growth,” said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. “The Board is looking forward to collaborating with Shalini, whose extensive experience in leading innovative global pharmaceutical companies will be invaluable as we enter new markets, advance our pipeline of groundbreaking cancer therapies, and embark on a transformative growth phase. Her financial expertise and proven success in guiding global enterprises will be instrumental in driving our path to profitability while continuing to deliver impactful medicines to more patients worldwide.”
Ms. Sharp is a leading financial executive with extensive experience in the pharmaceutical and investment banking industries. She currently serves as a board member of Neurocrine Biosciences and Organon & Co. Previously, she served on the boards of Mirati Therapeutics, Sutro Biopharma, Precision Biosciences, Panacea Acquisition Corp., Array Biopharma, and Agenus Inc.
Ms. Sharp previously served as Chief Financial Officer and Executive Vice President at Ultragenyx, as well as Chief Financial Officer and Vice President at Agenus. She previously held positions at Elan Pharmaceuticals, McKinsey & Company, and Goldman Sachs.
“I am honored to join BeiGene’s Board of Directors at a time of rapid global growth for the Company,” said Ms. Sharp. “BeiGene’s commitment to innovation and differentiated mission to lower barriers to access around the world resonate deeply with me, and I’m excited to work with the Board to impact even more patients’ lives.”
Ms. Sharp holds a B.A. and an MBA from Harvard University.
The full Board of Directors list is available on the BeiGene website at https://www.beigene.com/our-company-and-people/leadership-and-board/#CorporateLeaders.
About BeiGene
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the expected contributions of the new board member, BeiGene’s ability to advance its pipeline and progress towards transformative growth and sustainable profitability and BeiGene’s plans, commitments, aspirations, and goals under the caption “About BeiGene”. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240926501587/en/
Investor
Liza Heapes
+1 857-302-5663
ir@beigene.com
Media
Kyle Blankenship
+1 667-351-5176
media@beigene.com
Source: BeiGene, Ltd.
FAQ
When will Shalini Sharp join BeiGene's Board of Directors?
What positions will Shalini Sharp hold on BeiGene's Board?
What is Shalini Sharp's background in the pharmaceutical industry?
How might Shalini Sharp's appointment impact BGNE stock?
